Literature DB >> 11904143

Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists.

Michael C Goodnough1, George Oyler, Paul S Fishman, Eric A Johnson, Elaine A Neale, James E Keller, William H Tepp, Mike Clark, Stephanie Hartz, Michael Adler.   

Abstract

A targeted delivery vehicle (DV) was developed for intracellular transport of emerging botulinum neurotoxin (BoNT) antagonists. The DV consisted of the isolated heavy chain (HC) of BoNT/A coupled to a 10-kDa amino dextran via the heterobifunctional linker 3-(2-pyridylthio)-propionyl hydrazide. The HC served to target BoNT-sensitive cells and promote internalization of the complex, while the dextran served as a platform to deliver model therapeutic molecules to the targeted cells. To determine the ability of this chimeric glycoprotein to enter neurons, dextran and HC were labeled independently with the fluorescent dyes Oregon green 488 and Cy3, respectively. Internalization of DV was monitored in primary cortical cells using laser confocal microscopy. Incubation of cells for 24 h with DV resulted in discrete punctate labeling of both soma and processes. The Cy3 and Oregon green 488 signals were generally co-localized, suggesting that the complex remained in the same intracellular compartment during the initial 24 h. The DV-associated fluorescence was reduced progressively by co-application of increasing concentrations of unlabeled BoNT/A holotoxin. The results suggest that the BoNT/A HC is able to mediate internalization of a coupled dextran, even though the latter bears no resemblance to the BoNT/A light chain (LC). The HC of BoNT/A thus offers promise as a selective carrier to deliver BoNT antagonists to the nerve terminal cytoplasm for inhibiting the proteolytic activity of internalized BoNT/A LC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11904143     DOI: 10.1016/s0014-5793(02)02268-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting.

Authors:  Mengfei Ho; Li-Hsin Chang; Melissa Pires-Alves; Baskaran Thyagarajan; Jordan E Bloom; Zhengrong Gu; Karla K Aberle; Sasha A Teymorian; Yuka Bannai; Steven C Johnson; Joseph J McArdle; Brenda A Wilson
Journal:  Protein Eng Des Sel       Date:  2010-11-04       Impact factor: 1.650

2.  Neuronal delivery of antibodies has therapeutic effects in animal models of botulism.

Authors:  Patrick M McNutt; Edwin J Vazquez-Cintron; Luis Tenezaca; Celinia A Ondeck; Kyle E Kelly; Mark Mangkhalakhili; James B Machamer; Christopher A Angeles; Elliot J Glotfelty; Jaclyn Cika; Cesar H Benjumea; Justin T Whitfield; Philip A Band; Charles B Shoemaker; Konstantin Ichtchenko
Journal:  Sci Transl Med       Date:  2021-01-06       Impact factor: 17.956

Review 3.  Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

4.  Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.

Authors:  Mengfei Ho; Cheong-Hian Goh; Michael C Brothers; Shihua Wang; Ryan L Young; Yuxiang Ou; Juliana Nga-Man Lui; Marinos Kalafatis; Xiuwan Lan; Abigail E Wolf; Chad M Rienstra; Brenda A Wilson
Journal:  Protein Sci       Date:  2012-03       Impact factor: 6.725

5.  Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery.

Authors:  Philip A Band; Steven Blais; Thomas A Neubert; Timothy J Cardozo; Konstantin Ichtchenko
Journal:  Protein Expr Purif       Date:  2010-01-04       Impact factor: 1.650

6.  Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E.

Authors:  Harry B Hines; Alexander D Kim; Robert G Stafford; Shirin S Badie; Ernst E Brueggeman; David J Newman; James J Schmidt
Journal:  Appl Environ Microbiol       Date:  2007-12-14       Impact factor: 4.792

7.  Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery.

Authors:  Edwin J Vazquez-Cintron; Phillip H Beske; Luis Tenezaca; Bao Q Tran; Jonathan M Oyler; Elliot J Glotfelty; Christopher A Angeles; Aurelia Syngkon; Jean Mukherjee; Suzanne R Kalb; Philip A Band; Patrick M McNutt; Charles B Shoemaker; Konstantin Ichtchenko
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

8.  Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.

Authors:  Jerry O Conway; Laura J Sherwood; M Thelma Collazo; John A Garza; Andrew Hayhurst
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

9.  An efficient drug delivery vehicle for botulism countermeasure.

Authors:  Peng Zhang; Radharaman Ray; Bal Ram Singh; Dan Li; Michael Adler; Prabhati Ray
Journal:  BMC Pharmacol       Date:  2009-10-27

10.  Atoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasm.

Authors:  Edwin J Vazquez-Cintron; Maksim Vakulenko; Philip A Band; Larry H Stanker; Eric A Johnson; Konstantin Ichtchenko
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.